Compare NXRT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXRT | CGEM |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 761.7M | 780.4M |
| IPO Year | 2014 | 2020 |
| Metric | NXRT | CGEM |
|---|---|---|
| Price | $28.25 | $15.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $36.00 | $28.80 |
| AVG Volume (30 Days) | 167.6K | ★ 703.4K |
| Earning Date | 05-27-2026 | 03-30-2026 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,281,000.00 | N/A |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $4.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.69 | $5.68 |
| 52 Week High | $43.13 | $15.19 |
| Indicator | NXRT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 74.56 |
| Support Level | $27.69 | $6.75 |
| Resistance Level | $32.12 | N/A |
| Average True Range (ATR) | 0.85 | 0.99 |
| MACD | -0.20 | 0.28 |
| Stochastic Oscillator | 11.06 | 77.70 |
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.